Page last updated: 2024-12-05
pipenzolate
Description
Pipenzolate is a synthetic anticholinergic drug that acts as a muscarinic antagonist. It was initially developed for the treatment of gastrointestinal disorders, such as peptic ulcers, irritable bowel syndrome, and diarrhea. Pipenzolate works by blocking the action of acetylcholine at muscarinic receptors, which are found in the smooth muscles of the gastrointestinal tract. This results in decreased muscle contractions and reduced motility. Research on pipenzolate has focused on its pharmacological properties, mechanisms of action, and therapeutic potential. However, its use has been limited due to potential side effects, such as dry mouth, blurred vision, and urinary retention. Further studies are needed to investigate the safety and efficacy of pipenzolate for specific medical conditions. It is also of interest in the study of the effects of anticholinergics on the nervous system.'
pipenzolate: RN given refers to parent cpd; NM refers to bromide; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
Synonyms (54)
Synonym |
KBIO1_000638 |
DIVK1C_000638 |
SPECTRUM_001304 |
SPECTRUM5_001065 |
BSPBIO_002992 |
IDI1_000638 |
PRESTWICK2_000760 |
BPBIO1_000858 |
piperidinium, 1-ethyl-3-((hydroxydiphenylacetyl)oxyl)-1-methyl- |
brn 1506094 |
piperidinium, 1-ethyl-3-hydroxy-1-methyl-, benzilate (ester) |
pipenzolate |
einecs 236-748-1 |
1-ethyl-1-methyl-3-(oxidodiphenylacetoxy)piperidinium |
pipenzolonum |
1-ethyl-3-hydroxy-1-methylpiperidinium bromide benzilate |
AB00053816 |
BSPBIO_000780 |
KBIO2_006920 |
KBIO3_002492 |
KBIOGR_001108 |
KBIO2_001784 |
KBIO2_004352 |
KBIOSS_001784 |
PRESTWICK0_000760 |
PRESTWICK1_000760 |
SPBIO_001587 |
SPECTRUM2_001514 |
SPBIO_002719 |
SPECTRUM3_001546 |
NINDS_000638 |
SPECTRUM4_000754 |
PRESTWICK3_000760 |
(1-ethyl-1-methylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate |
NCGC00018203-02 |
unii-rs3k5yxv34 |
13473-38-6 |
5-21-01-00043 (beilstein handbook reference) |
rs3k5yxv34 , |
pipenzolate [who-dd] |
1-ethyl-3-hydroxy-1-methylpiperidinium benzilate |
CHEMBL1619528 |
pipenzolate cation |
pipenzolate ion |
DTXSID9048481 |
HY-B0953 |
AB00053816_15 |
AB00053816_16 |
CHEBI:95178 |
2-hydroxy-2,2-diphenylacetic acid (1-ethyl-1-methyl-3-piperidin-1-iumyl) ester |
SBI-0051757.P002 |
DB13844 |
Q2096435 |
BRD-A53561827-004-15-7 |
Drug Classes (1)
Class | Description |
diarylmethane | Any compound containing two aryl groups connected by a single C atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 7 (77.78) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (11.11) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 26.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 26.50 (24.57) | Research Supply Index | 2.30 (2.92) | Research Growth Index | 4.13 (4.65) | Search Engine Demand Index | 29.35 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |